Objectives: Based on outcomes of the BIOSOLVE-II study, a novel second generation drugeluting absorbable metal scaffold gained CE-mark in 2016. The BIOSOLVE-III study aimed to confirm these outcomes and to obtain additional 12-month angiographic data.
Results: Mean patient age was 65.5 6 10.8 years and mean lesion reference diameter was 2.70 6 0.43 mm. In BIOSOLVE-III, there were significantly more type B2/C lesions than in BIOSOLVE-II (80.3% versus 43.4%, P < 0.0001) and significantly more moderate-to-severe calcifications (24.2% versus 10.7%, P 5 0.014). At 12 months, there was no difference in late lumen loss between the two studies; in the overall population, it was 0.25 6 0.31 mm in-segment and 0.39 6 0.34 mm inscaffold. Target lesion failure occurred in six patients (3.3%) and included two cardiac deaths, one target-vessel myocardial infarction, and three clinically driven target lesion revascularizations. No definite or probable scaffold thrombosis was observed.
Conclusion:
The pooled outcomes of BIOSOLVE-II and BIOSOLVE-III provide further evidence on the safety and performance of a novel drug-eluting absorbable metal scaffold with constant clinical and angiographic performance parameters at 12 months and no definite or probable scaffold thrombosis.
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| I N TR ODU C TI ON
Bioresorbable vascular scaffolds (BRS) were developed to overcome some of the possible long-term effects of permanent stents. The absence of a permanent caged vessel segment might reduce effects such as chronic vessel wall inflammation, stent crushing, and fractures, preserve options of noninvasive vessel lumen imaging, and facilitate surgical or percutaneous repeat coronary revascularization [1] [2] [3] .
The second generation drug-eluting absorbable metal scaffold (DREAMS 2G, Biotronik AG, Buelach, Switzerland) was successfully tested in the BIOSOLVE-II study and the device gained CE-mark in June 2016. The aim of BIOSOLVE-III was to confirm the positive outcomes of BIOSOLVE-II with the commercial, slightly modified product (now being called Magmaris) and to collect additional 12-month angiographic data. These data are highly relevant as 12 months reflect the end of the absorption time [4] .
| M A TE RI A L S A ND M E TH ODS

| Study design and population
The study designs of BIOSOLVE-II and BIOSOLVE-III have been previously described [5] . In brief, BIOSOLVE-II and BIOSOLVE-III are prospective, multicenter studies assessing the safety and performance of DREAMS 2G in de novo lesions at 13 (BIOSOLVE-II) and 8 (BIO-SOLVE-III) centers in Europe, South America, and Asia. From October 2013 to May 2015, 123 patients were enrolled in BIOSOLVE-II, and from March to September 2016, 61 patients were enrolled in BIOSOLVE-III. The study conduct was in compliance with the Declaration of Helsinki, Good Clinical Practice, ISO14155, the studies were approved by the institutional ethics committees, and all patients provided written informed consent prior to any study procedures.
Inclusion and exclusion criteria are listed at ClinicalTrials.gov (NCT01960504 and NCT02716220). The main inclusion criteria were stable or unstable angina or documented silent ischemia, a maximum of two single de novo lesions in two separate coronary arteries, reference vessel diameter of 2.2-3.7 mm for device diameters of 2.5 to 3.5 mm, lesion length 21 mm, and a diameter stenosis 50% and <100%.
Main exclusion criteria were severe calcification, three-vessel disease, ostial target lesions within 5 mm of vessel origin, target lesions involving a side branch >2 mm, target lesion located in or supplied by an arterial or venous bypass graft, and unsuccessful predilatation.
Both studies had clinical follow-ups at 1, 6, 12, 24, and 36 months.
Angiographic follow-up was scheduled at 6 months for BIOSOLVE-II and at 12 months for BIOSOLVE-III. Furthermore, angiographic data at 36 months will be collected in BIOSOLVE-II. If additional angiographic follow-ups were performed, this information was collected as well.
| Study device
DREAMS 2G has been described previously [4] . It is made from magnesium alloy scaffold with a strut thickness and width of 150 mm. The scaffold is covered by sirolimus in combination with a bioresorbable PLLApolymer, the same drug-polymer combination that is successfully used in the commercially available Orsiro drug-eluting stent (Biotronik AG, Buelach, Switzerland) [6] [7] [8] . The device was available in diameters of 2.5, 3, and 3.5 mm and length of 15, 20, and 25 mm for BIOSOLVE-II, and diameters of 3 and 3.5 mm, and length of 15, 20, and 25 mm for BIOSOLVE-III.
| Endpoints
The primary endpoints were late lumen loss at 6-month follow-up (BIOSOLVE-II) and procedure success (BIOSOLVE-III). Procedure success was defined as final diameter stenosis of <30% by quantitative coronary angiography without occurrence of in-hospital death, Q-wave or non-Q-wave myocardial infarction or repeat target lesion revascularization (TLR). Secondary endpoints were target lesion failure, a composite of cardiac death, target vessel Q-wave and non-Q-wave myocardial infarction according to the Society for Cardiovascular Angiography and Interventions definitions [9] , or clinically driven TLR; and scaffold thrombosis [10] . Secondary angiographic endpoints were in-segment and in-scaffold binary restenosis rate, diameter stenosis, and late lumen loss. A clinical event committee adjudicated all adverse events, and angiographic data were analyzed by an independent core laboratory.
Endpoints up to 6 months have been reported previously [4, 5] .
| Procedure
Predilatation was mandatory. The size of the predilatation balloon had to be 0.5 mm smaller than the reference vessel diameter but not larger than the reference vessel; its length had to be shorter or the same as the lesion length. Only one study device per lesion was allowed, although in bailout situations a second DREAMS 2G could be used, and, in case of failure, an Orsiro drug-eluting stent. Postdilatation could be performed at the discretion of the investigator, but the maximum inner diameter of the DREAMS 2G (as indicated on the label) was not allowed to be exceeded. In addition, the postdilatation balloon had to be shorter than the scaffold. Dual antiplatelet therapy was recommended for a minimum of 6 months.
If no scaffold could be implanted, the patient counted for procedure success only, but was excluded from further follow-up. Figure 4 shows a case example, which demonstrates the resorption of the device and a homogeneous endothelialization and completion of the healing process despite initial malapposition, dissection, and plaque protrusion.
| Statistical analysis
Target lesion failure was observed in six patients (3.3% 
| Discussion
Pooled outcomes of the BIOSOLVE-II and BIOSOLVE-III studies further confirm the safety and performance of DREAMS 2G at 12 months with clinical outcomes comparable to contemporary drug-eluting stents. In particular the absence of definite or probable scaffold thrombosis is remarkable. A recent state of the art paper raised concerns related to the higher device thrombosis risks of polymeric BRS within the first few years prior to complete bioresorption [3] . In contrast to current CE-marked drug-eluting polymeric scaffolds with a resorption time up to 3 years, the magnesium scaffold backbone is nearly fully absorbed within one year and at 6 months struts are not discernable by optical coherence tomography (OCT) anymore [3, 4, 11, 12] . Therefore the conclusion of overall safety related to scaffold thrombosis is already justified for DREAMS 2G/Magmaris in this early phase as 12-month outcomes somewhat reflect 3-year outcomes of ABSORB (Abbott Vascular, Santa Clara, California) for which so far, no scaffold thrombosis beyond the resorption period of 3 years was observed in the ABSORB and ABSORB-II studies [3, 13, 14] . Likewise, the recommended dual antiplatelet therapy for Magmaris is shorter than for polymeric scaffolds as recent state of the art papers discuss a prolonged dual antiplatet therapy covering the complete biodegradation time of the BRS [3, 15] .
Design features that might support the absence of scaffold thrombosis have been reported previously (e.g., metal-stent-like behavior and laser polishing for a smooth surface facilitating the embedding into the vessel wall, and reducing pulsatile shear stress), as well as OCT outcomes that showed no intraluminal mass and no malapposed struts at 6 and 12 months [4, 11, 12] . A porcine arterio-venous shunt model demonstrated significantly less platelet adherence, thrombus deposition, and inflammatory cell adhesion for DREAMS 2G compared to ABSORB, and similar results to the Orsiro drug-eluting stent [16] . Furthermore, a study in porcine and rabbit models showed less thrombus formation for DREAMS 2G compared to ABSORB [17] .
Performance parameters were assessed using late lumen loss and TLR. Constant late lumen loss between 6 and 12 months has been reported earlier for BIOSOLVE-II [11] . Interestingly, in BIOSOLVE-III, late lumen loss was nearly identical to BIOSOLVE-II despite more complex lesions with significant higher type B2/C lesions and calcification.
No target lesion failure was observed between 6 and 12 months, leading to a 12-month rate of 3.3%. In comparison, in a patient-level pooled meta-analysis including 3389 patients, 12-month target lesion failure was 6.6% for ABSORB, 5.2% for a contemporary everolimuseluting permanent stent [18] , and 5.7% for the 122 patients enrolled in the DESolve trial [19] . shows a mid LAD lesion with adequate lesion preparation in accordance to the "4Ps "with a balloon to artery ratio of 1:1 and achievement of less than 20% residual diameter stenosis. During predilatation a dissection occurred which was covered by the implanted DREAMS 2G (3 3 20 mm). At 6 and 12 months the lumen is well preserved. Optical coherence tomography in panel (C) shows well embedded struts at baseline. At 6 months, struts are hardly discernable anymore and embedded in the vessel wall with homogeneous endothelial coverage. The struts covering the septal branch at baseline disappeared over time. Lumen enlargement between 6 and 12 months is visible in all frames Even though these outcomes are encouraging, it should be appreciated that this is a novel technology requiring meticulous attention to patient selection and implant technique. Proper patient and lesion selection, proper sizing, and predialation and postdilatation ("4P"-strategy), as described in a recent consensus paper is paramount [20] . A summary of the consensus paper together with some current tips are provided below:
Patient and lesion selection: Patients who may benefit from a scaffold are those with a long life expectancy (>5 years), possible return to Predilatation: should be done with a noncompliant balloon with a 1:1 balloon-to-artery ratio until full expansion; residual diameter stenosis should be 20% (minimum 2.5 mm).
Implantation: Implanting balloon inflation should be done until full and homogenous expansion, but maximum rated burst pressure should be respected. QCA should be used to control the implant results; OCT or IVUS is useful during the learning phase.
Postdilatation is helpful optimizing scaffold strut embedding to limit shear stress related thrombus formation [21] . It should be done with a noncompliant balloon at >16 atm with the same or maximally 0.5 mm larger diameter compared to the Magmaris scaffold. Image enhancement technologies or marker wires help identifying the Magmaris markers; a change of projection plane may also be helpful.
| Limitations
Our series has potential limitations, (a) the fact that predominantly patients with limited clinical complexity and short lesions were included restricts the study interpretation to these patient and lesion characteristics, (b) as angiographic follow-up at 12 months was not mandatory, 12-month late lumen loss of only 35.5% of BIOSOLVE-II patients is available, (c) the implantation technique varied from the current "4P" strategy, (d) the lack of control hampers the comparison to other devices, and (e) patient numbers are not sufficient for a robust assessment of rare events such as scaffold thrombosis. Results need to be confirmed in larger patient series such as the currently enrolling BIOSOLVE-IV registry.
| Conclusion
Twelve-month data of BIOSOLVE-II were validated in BIOSOLVE-III providing further evidence on the safety and performance of a second generation absorbable metal scaffold with constant performance parameters at 12 months and no definite or probable scaffold thrombosis.
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